Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

2016 Overview

Julia Lee
November 28, 2016

Market Update

Julia Lee
November 17, 2016

Peter Quinton on Trump’s victory

Bell Direct
November 17, 2016

Bell Potter: Banks post-results review

Bell Direct
November 11, 2016

mFund series: Peters MacGregor

Bell Direct
October 11, 2016

mFund series: RARE Infrastructure

Bell Direct
October 11, 2016

Bell Potter: Five standout stocks

Bell Direct
October 7, 2016

September newsletter Julia’s insights

Julia Lee
September 29, 2016